LYNGE, DENMARK – WSA, a global hearing healthcare group, reported financial results for the second quarter of fiscal year 2024/25 (January 1–March 31, 2025), with organic revenue growth of 1% and a 22% increase in EBITDA. This reflects an improvement of 2.8 percentage points in the company’s EBITDA margin.
“With an organic revenue growth of 1% in a volatile macro environment and a significant EBITDA margin improvement WSA, delivered satisfactory second quarter results. I am very pleased with the successful launch of Signia BCT IX and Widex Allure at the end of the quarter. With our complementary and distinct Signia and Widex brand platforms, we are committed to delivering an uncompromising hearing experience that meets the unique needs of the largest groups of people with hearing loss and the hearing care professionals serving them”
–Jan Mäkelä, CEO of WSA
Q2 2024/25 Financial Highlights
- Organic revenue increased by 1% (compared to 7% in Q2 last year), totaling EUR 655 million. The quarter was affected by softer demand ahead of product launches and a slower commercial market in the U.S.
- Reported revenue grew by 2% (4% last year) to EUR 668 million, aided by favorable currency effects, mainly due to a stronger USD against the EUR.
- EBITDA rose 22% to EUR 117 million, representing a margin of 17.5% (14.7% in the same period last year).
Product Launches in Q2
- In February, WSA introduced Signia BCT IX, a hearing aid with universal device connectivity. External research confirmed that the Signia IX platform outperforms competitors in noisy group conversations, supporting improved speech understanding.
- In March, WSA launched the Widex Allure platform along with Widex Compass Cloud, the industry’s first cloud-based hearing aid fitting software. The Allure platform is designed to provide clear speech and immersive environmental sound. Compass Cloud aims to improve first-fit outcomes and provide an intuitive experience for hearing care professionals.
1H 2024/25 Financial Highlights
- Reported revenue for the first half of the fiscal year was EUR 1,337 million, representing 3% organic growth (10% in 1H last year), compared to a strong prior-year period following the initial launch of Signia IX.
- EBITDA for the period reached EUR 231 million, with a margin of 17.3% (up from 15.8%).
Outlook for FY 2024/25
Jan Mäkelä
WSA has maintained its full-year outlook of 3–6% organic revenue growth, supported by its product portfolio and recent product launches. The EBITDA margin before special items is expected to increase by 1–2 percentage points, driven by the company’s ongoing profitable growth initiatives.
References:
- Measured as EBITDA before special items and net of R&D Capex.
- Jensen NS, Samra B, Best S, Wilson C, Taylor B. 2025. 86% of participants performed better with Signia Integrated Xperience versus key competitor in noisy group conversation. Signia blog post retrieved at https://www.signia-pro.com/en/blog/global/2025-04-study-86-percent-performed-better-with-signia-ix/
About WS Audiology
WSA is a leading global pure-play hearing healthcare group, pioneering innovative technologies for over 140 years, helping millions of people with hearing loss regain their hearing, engage in meaningful conversations, and participate fully in society. WSA operates in over 130 markets and employs more than 12,500 people across our innovative brand platforms, Widex and Signia, and a global network of hearing care professionals and consumer-facing businesses. WSA is privately owned by the Tøpholm and Westermann families, the Lundbeck Foundation, EQT and ATHOS KG. Learn more at www.wsa.com.
Source: WSA
